Skip to main content
RT @Yuz6Yusof: In a UK study of newly diagnosed #SLE (within 12 months of meeting ACR criteria), Dr Yee reported BILAG-2

Md Yuzaiful Md Yusof Yuz6Yusof

5 years 4 months ago
In a UK study of newly diagnosed #SLE (within 12 months of meeting ACR criteria), Dr Yee reported BILAG-2004 Grade A or B was predictive of damage in the median FU of 73 months. MMF use appeared to be protective #EULAR2021 #POS0705 @RheumNow https://t.co/VROqTTrzwY
RT @Yuz6Yusof: Is efficacy of #voclosporin in #lupus nephritis sustained at 2 years? N=116 pts on VOC and N=100 pts on P

Md Yuzaiful Md Yusof Yuz6Yusof

5 years 4 months ago
Is efficacy of #voclosporin in #lupus nephritis sustained at 2 years? N=116 pts on VOC and N=100 pts on Placebo enrolled in Extension Study. Dr Saxena reported patients on VOC continued meaningful ⬇️in uPCR and stable eGFR up to 2yrs vs Placebo #EULAR2021 #POS0681 @RheumNow https://t.co/M5MX7tW2CA
RT @chriswincup: Still time to sign up for a place in today’s #lupus interest group at #EULAR2021 (last few spaces re

Chris Wincup chriswincup

5 years 4 months ago
Still time to sign up for a place in today’s #lupus interest group at #EULAR2021 (last few spaces remaining) 🕒12:30 CEST / 11:30 UK 🧬 "Lupus, the next 10 years" 🔬where we will be joined by @edvital 📍Click EULAR Networking then Interest Group Discussion to join @EMEUNET https://t.co/6r7RYOi8VG
RT @Yuz6Yusof: Once approved, in what type of patients with #psoriaticarthritis would you treat with IL23-inhibitors? #E

Md Yuzaiful Md Yusof Yuz6Yusof

5 years 4 months ago
Once approved, in what type of patients with #psoriaticarthritis would you treat with IL23-inhibitors? #EULAR2021 #OP0228 #OP0230 @RheumNow 🤔
RT @Yuz6Yusof: #Lupus Interest Group Meeting #EULAR2021. Working towards personalised medicine to improve treatment of o

Md Yuzaiful Md Yusof Yuz6Yusof

5 years 4 months ago
#Lupus Interest Group Meeting #EULAR2021. Working towards personalised medicine to improve treatment of our patients with lupus. Future of #SLE research are in good hands 👌#NEXTGEN @edvital @GeorgeARobinson @pekor002 @dalilatm Matteo Boemi, Teona @eular_org https://t.co/eK4oiwlJZO
RT @Yuz6Yusof: Utility of salivary gland biopsy in #Sjogren?Dr Chatzis analysed biopsy from N=618 with =>1 yr FU befo

Md Yuzaiful Md Yusof Yuz6Yusof

5 years 4 months ago
Utility of salivary gland biopsy in #Sjogren?Dr Chatzis analysed biopsy from N=618 with =>1 yr FU before 🔼lymphoma. 58/618 developed lymphoma. Predictors identified were⬆️Focus Score, cryoglobulin & parotid swelling. FS=>4 predicted earlier lymphoma #EULAR2021 #OP0291 @RheumNow https://t.co/yFFZpBRvji
RT @KDAO2011: In case you're not convinced:
Another study showed HCQ protects SLE pts from death. Risk reduction in thos

k dao KDAO2011

5 years 4 months ago
In case you're not convinced: Another study showed HCQ protects SLE pts from death. Risk reduction in those taking antimalarials 83% vs. those who cannot take the drug (for any reason) 42%, yet 60% of patients are non-adherent -study reviewed by Prof Dorner #EULAR2021 @rheumnow https://t.co/zBgCLipHPP
RT @Yuz6Yusof: Can we identify 1st Trimester predictors of adverse pregnancy outcome (APO) in #lupus? Dr Larosa studied

Md Yuzaiful Md Yusof Yuz6Yusof

5 years 4 months ago
Can we identify 1st Trimester predictors of adverse pregnancy outcome (APO) in #lupus? Dr Larosa studied women in 🇫🇷 (N=238; 98% on #HCQ; 86% had SLEDAI=0). 34(14%) had APO. Higher SLICC damage and LAC+ve predicted APO but not LLDAS/DORIS Remission #EULAR2021 #OP0295 @RheumNow https://t.co/423sSEKLFY
RT @Yuz6Yusof: Why do black women with #lupus have poor #HRQoL? Dr Kimble used untargeted metabolomic profiling in N=23

Md Yuzaiful Md Yusof Yuz6Yusof

5 years 4 months ago
Why do black women with #lupus have poor #HRQoL? Dr Kimble used untargeted metabolomic profiling in N=23 black women SLE and N=21 black women nonSLE. The former had profiles consistent with⬇️energy production resulted in ⬆️fatigue and other symptoms #EULAR2021 #POS0173 @RheumNow https://t.co/GYzmpf8GwW
RT @Yuz6Yusof: More novel target (IL23-i; Risankizumab) for #psoriaticarthritis👏. Dr Ostor presented results from Pha

Md Yuzaiful Md Yusof Yuz6Yusof

5 years 4 months ago
More novel target (IL23-i; Risankizumab) for #psoriaticarthritis👏. Dr Ostor presented results from Phase III KEEPsAKE2. 46% of patients were Bio-IR. 51.3% of RZB-treated vs 26.5% Placebo-tx achieved ACR20 response at 6mo (p<0.001). No major safety #EULAR2021 #OP0228 @RheumNow https://t.co/6AIGCNMApv
RT @Yuz6Yusof: Is Dissociation a component of #lupus brain fog ☁️? Dr Monahan administered DES scale (score =&gt;25

Md Yuzaiful Md Yusof Yuz6Yusof

5 years 4 months ago
Is Dissociation a component of #lupus brain fog ☁️? Dr Monahan administered DES scale (score =>25 = Dissociation) to N=339 pts; of which 97 (27%) had NPSLE. Only 13% had abnormal score. No difference in score btw NPSLE vs non-NPSLE #EULAR2021 #POS0709 @RheumNow https://t.co/aarL8gdCDM
RT @doctorRBC: Israeli study of all cause mortality in PsA vs general population
⭐️no increased mortality in PsA gro

Robert B Chao, MD doctorRBC

5 years 4 months ago
Israeli study of all cause mortality in PsA vs general population ⭐️no increased mortality in PsA group ⭐️leading causes of death was cancer in both groups ⭐️age, male sex, BMI, socioeconomic status, PsO associated with ⬆️mortality, NOT DMARDs Abs#OP0219 #EULAR2021 @RheumNow
RT @RichardPAConway: Dr Bilgin presents on PLEX in AAV. I'm not a believer post-PEXIVAS despite attempts to slice and di

Richard Conway RichardPAConway

5 years 4 months ago
Dr Bilgin presents on PLEX in AAV. I'm not a believer post-PEXIVAS despite attempts to slice and dice that data and this seems to show no evidence to change my mind @RheumNow #EULAR2021 Abstr#POS0255 https://t.co/U3zwt619lc
RT @Stiddyo: #POS0221 retrospective propensity score corrected observational study TOFA (n:156) vs. BARI (n:138): week 2

Paul Studenic Stiddyo

5 years 4 months ago
#POS0221 retrospective propensity score corrected observational study TOFA (n:156) vs. BARI (n:138): week 24: CDAI REM (see pic) BARI>TOFA. Factors of treatment resistence in TOFA: OR: Nr of prior bDMARD 1.77 & HAQ-DI 18.6 No such factors in BARI identified. #EULAR2021 @RheumNow https://t.co/u9Nati2ZJO
RT @RheumNow: Is Rituximab and Belimumab the Combination to Beat Lupus? by Dr. Eric Dein (@ejdein1) #EULAR2021

On day

Dr. John Cush RheumNow

5 years 4 months ago
Is Rituximab and Belimumab the Combination to Beat Lupus? by Dr. Eric Dein (@ejdein1) #EULAR2021 On day 2 of EULAR , Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab. https://t.co/r4aNG7KR5h https://t.co/nppgRytnlr
×